Navigation Links
BioMarin to Host Third Quarter 2009 Financial Results Conference Call and Webcast on Wednesday, October 28 at 5:00 p.m. ET
Date:9/30/2009

NOVATO, Calif., Sept. 30 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, October 28, at 5:00 p.m. ET to discuss third quarter 2009 financial results.

    U.S. / Canada Dial-in Number:  800.299.6183
    International Dial-in Number:  617.801.9713
    Participant Code: 51404008
    Replay Dial-in Number: 888.286.8010
    Replay International Dial-in Number: 617.801.6888
    Replay Code: 51416825

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com. A replay of the call will be archived on the site for one week following the call.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase I/II clinical development for the treatment of MPS IVA. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin®, Naglazyme® and Kuvan® are registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC.


    Contacts:

    Investors                                   Media
    Eugenia Shen                                Susan Berg
    BioMarin Pharmaceutical Inc.                BioMarin Pharmaceutical Inc.
    (415) 506-6570                              (415) 506-6594

SOURCE BioMarin Pharmaceutical Inc.


'/>"/>
SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. BioMarin to Present at the Morgan Stanley Healthcare Conference
2. BioMarin to Present at the Baird Healthcare Conference
3. BioMarin to Present at the Jefferies Healthcare Conference
4. BioMarin to Present at the Goldman Sachs Healthcare Conference
5. BioMarin to Present at the Deutsche Bank Health Care Conference
6. BioMarin to Present at the Baird Growth Stock Conference
7. BioMarin Announces First Quarter 2009 Financial Results
8. BioMarin to Host First Quarter 2009 Financial Results Conference Call and Webcast on Thursday, April 30 at 5:00 p.m. ET (23:00 CET)
9. BioMarin Receives Notice of Allowance for Once Daily Dosing Patent for Kuvan
10. BioMarin to Present at the 4th Annual Citi Biotech Day
11. BioMarins Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2017)... (PRWEB) , ... June 27, 2017 , ... ... design for its patented GX-1 yeast production and fermentation process. The efficiencies ... that rely on micro-organism technologies, most notably the ethanol industry wherein individual production ...
(Date:6/26/2017)... (PRWEB) , ... June 26, 2017 , ... ... that Melissa Kirkegaard, the former Associate Director of Product Development R&D at Allergan ... and pharmaceutical products at both start-up and established biopharma companies, has joined the ...
(Date:6/26/2017)... ... June 26, 2017 , ... The Workgroup for Electronic Data Interchange (WEDI) ... efficiencies in healthcare information exchange and a statutory advisor to the U.S. Department of ... federal Office of the National Coordinator for Health Information Technology, will deliver the keynote ...
(Date:6/23/2017)... ... 23, 2017 , ... Biova, LLC., the leader in water soluble egg membrane ... Dr. Henig will bring a wealth of scientific experience in the food, beverage, nutrition ... and Scientific Officer of four major global companies in the last 4 decades. ...
Breaking Biology Technology:
(Date:3/30/2017)... , March 30, 2017 Trends, opportunities and ... and behavioral), by technology (fingerprint, AFIS, iris recognition, facial ... and others), by end use industry (government and law ... financial and banking, and others), and by region ( ... , Asia Pacific , and the ...
(Date:3/24/2017)... 2017 The Controller General of Immigration from Maldives ... Algeen have received the prestigious international IAIR Award for the most ... Reading ... Maldives ... Abdulla Algeen (small picture on the right) have received the IAIR award ...
(Date:3/22/2017)... , March 21, 2017   Neurotechnology , ... recognition technologies, today announced the release of the ... which provides improved facial recognition using up to ... a single computer. The new version uses deep ... accuracy, and it utilizes a Graphing Processing Unit ...
Breaking Biology News(10 mins):